Arcturus Therapeutics (NASDAQ:ARCT) Shares Cross Below 200 Day Moving Average - Time to Sell?

Key Points

• Shares crossed below the 200-day moving average: ARCT fell beneath its 200‑day MA of $8.34, trading as low as $8.27 and last at $8.30 (down about 3.4%).
• Quarterly results disappointed: the company reported EPS of ($1.03) vs. ($0.92) expected and revenue of $7.2M vs. $14.32M expected, with a negative net margin (~80%) and analysts projecting ~-4.46 EPS for the year.
• Analyst views are mixed but average to a "Moderate Buy": one Strong Buy, several Buys and some cuts have produced an average price target of $29.50, despite recent downward revisions from firms like Citigroup and Piper Sandler.

Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Get Free Report) crossed below its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $8.34 and traded as low as $8.27. Arcturus Therapeutics shares last traded at $8.30, with a volume of 254,338 shares trading hands.

Analyst Upgrades and Downgrades

ARCT has been the subject of a number of recent analyst reports. Roth Mkm initiated coverage on shares of Arcturus Therapeutics in a report on Thursday, January 22nd. They set a "buy" rating and a $20.00 price target for the company. Citigroup cut their price target on shares of Arcturus Therapeutics from $66.00 to $21.00 and set a "buy" rating for the company in a report on Thursday, March 5th. Weiss Ratings upgraded shares of Arcturus Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a report on Tuesday, April 21st. B. Riley Financial initiated coverage on shares of Arcturus Therapeutics in a report on Wednesday, March 18th. They set a "buy" rating and a $22.00 price target for the company. Finally, Piper Sandler cut their price target on shares of Arcturus Therapeutics from $72.00 to $25.00 and set an "overweight" rating for the company in a report on Wednesday, March 4th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $29.50.

Arcturus Therapeutics Trading Down 3.4%

The stock's fifty day moving average price is $7.77 and its 200-day moving average price is $8.34. The firm has a market cap of $235.89 million, a price-to-earnings ratio of -3.49 and a beta of 2.44.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last announced its quarterly earnings results on Tuesday, March 3rd. The biotechnology company reported ($1.03) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.92) by ($0.11). The firm had revenue of $7.20 million for the quarter, compared to analyst estimates of $14.32 million. Arcturus Therapeutics had a negative return on equity of 29.13% and a negative net margin of 80.19%. Analysts predict that Arcturus Therapeutics Holdings Inc. will post -4.46 earnings per share for the current year.

Institutional Trading of Arcturus Therapeutics

Several institutional investors have recently added to or reduced their stakes in ARCT. ARK Investment Management LLC increased its holdings in Arcturus Therapeutics by 39.4% in the 4th quarter. ARK Investment Management LLC now owns 2,611,099 shares of the biotechnology company's stock valued at $16,006,000 after purchasing an additional 738,378 shares during the last quarter. Arrowstreet Capital Limited Partnership increased its holdings in Arcturus Therapeutics by 1,371.4% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 552,179 shares of the biotechnology company's stock valued at $10,177,000 after purchasing an additional 514,652 shares during the last quarter. Millennium Management LLC acquired a new stake in Arcturus Therapeutics in the 1st quarter valued at approximately $4,892,000. Bank of America Corp DE increased its holdings in Arcturus Therapeutics by 112.0% in the 3rd quarter. Bank of America Corp DE now owns 620,055 shares of the biotechnology company's stock valued at $11,428,000 after purchasing an additional 327,626 shares during the last quarter. Finally, Goldman Sachs Group Inc. increased its holdings in Arcturus Therapeutics by 170.3% in the 4th quarter. Goldman Sachs Group Inc. now owns 391,227 shares of the biotechnology company's stock valued at $2,398,000 after purchasing an additional 246,499 shares during the last quarter. Institutional investors and hedge funds own 94.54% of the company's stock.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc is a clinical-stage biotechnology company dedicated to developing messenger RNA (mRNA) medicines that address a range of diseases. The company leverages its proprietary STARR® mRNA platform to enable precise control over mRNA expression, supported by its lipid nanoparticle delivery technology, LUNAR®. Arcturus's approach is designed to address both therapeutic and prophylactic applications, with an emphasis on vaccines and treatments for rare genetic and infectious diseases.

The company's pipeline includes ARCT-810, an mRNA therapeutic candidate for phenylketonuria (PKU), and ARCT-021 (also known as LUNAR-COV19), a COVID-19 vaccine candidate developed in collaboration with Duke-NUS Medical School in Singapore.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.